Hirshberg Foundation for Pancreatic Cancer Research

Dedicated to advancing pancreatic cancer research and providing support to patients and their families.

Donate
  • ABOUT THE FOUNDATION
    • Agi’s Story
    • About Us →
      • Mission
      • Directors/Trustees
      • Scientific Advisory Board
      • How Our Journey Began
    • News →
      • Latest News
      • Research News
      • Foundation News
      • UCLA Activity Summary Reports
      • Newsletters
      • Press Room
    • Contact
  • PANCREATIC CANCER
    • About the Pancreas →
      • The Pancreas
      • Cancer Cells
      • Risk Factors
      • Symptoms
      • Diagnosis
      • Prognosis
      • Staging
      • Second Opinion
    • Treatment Options →
      • Surgery
      • Chemotherapy
      • Targeted Therapy
      • Radiation Therapy
      • Alternative Treatment Options
      • Clinical Trials
    • Supportive Care →
      • Obstructions
      • Pain Control
      • Nutrition
      • Cannabis
      • Palliative Care
    • Pancreatic Cancer Facts
    • Glossary of Terms
    • Frequently Asked Questions
  • RESEARCH
    • Seed Grant Program →
      • Seed Grant Recipients
      • Frequently Asked Questions
    • Seed Grant News
    • UCLA Program →
      • UCLA Center for Pancreatic Diseases
      • Basic Research
      • Translational Research
      • Sahin-Toth Laboratory
      • UCLA Pancreas Tissue Bank
      • UC Pancreatic Cancer Consortium
      • Simms/Mann Psychosocial →
        • Insights into Cancer
    • American Pancreatic Association
    • NIH Funded Projects
  • PATIENTS & CAREGIVERS
    • Patient Support
    • Where to Begin
    • Caregivers & Families
    • Symposium →
      • Symposium Presentations
    • Patient & Family Webinars
    • Genetic Counseling
    • Resources →
      • NCCN Guidelines for Patients
      • Patient Support Tools
      • Create Your Health Care Team
      • Patient Health Diaries
      • Support Groups
      • Financial Aid
  • HOW YOU CAN HELP
    • Planned Giving
    • Donor-Advised Funds
    • Event Calendar
    • Get Inspired
    • Fundraising Resources
    • November Awareness Month →
      • World Pancreatic Cancer Day
    • More Ways to Give →
      • You Can Help Funds
      • Host Your Own Event
      • Shop Online Store
      • Wedding Program
      • Volunteer
      • Car Program
  • SEARCH
Home / Research / Seed Grant Program / Seed Grant Recipients / Evan R. Abt, Ph.D.

Evan R. Abt, Ph.D.

Evan R. Abt Ph.D.
Evan R. Abt Ph.D.
Postdoctoral Researcher
Molecular and Medical Pharmacology

University of California, Los Angeles (UCLA)
Los Angeles, CA

Identification of actionable immuno-metabolic vulnerabilities of pancreas cancer tumors elicited by mutant-selective KRAS inhibitors

Overview

Aim: Therapy

KRAS mutations are the most common drivers of pancreatic ductal adenocarcinoma (PDAC). The recent groundbreaking discovery and clinical translation of mutant KRAS specific inhibitors has reinvigorated hope for direct targeting of this dominant driver oncogene in PDAC formerly deemed “undruggable.” However, it is becoming increasingly clear that they alone are insufficient to induce durable tumor regressions and that the therapeutic potential of mutant KRAS inhibitors will only be realized if they are administered as components of rationally designed combination therapies. Thus, we aim to develop effective combinations which leverage vulnerabilities elicited by KRAS inhibition and are suitable for clinical application. We found that while KRAS inhibitors potently restrict the growth of PDAC tumor cells, they also trigger the production the immunosuppressive metabolite adenosine, suggesting that simultaneous inhibition of adenosine signaling in the tumor microenvironment may be required to incite anti-tumor immune responses. This project will focus on (i) characterizing the mechanism of adenosine release by PDAC cells following KRAS inhibition and applying this information to guide the choice of companion therapies; and (ii) evaluating combinations of mutant KRAS inhibitors, adenosine signaling blockade and immune checkpoint blockade in PDAC models in mice. Collectively, our studies will generate new insight into the immuno-metabolic effects of KRAS inhibitors while providing the rationale for combination therapies.

Patient Support Resources

from the comfort of your home


Our Webinar Library »

Never Give Up.
The journey continues with an end in sight.
Our Stories »
SUBSCRIBE
Our Free E-Newsletter
Sign up to receive information on breaking news, patient programs and upcoming events.
You can custom tailor your subscriptions and unsubscribe at any time.
  • How You Can Help
  • Make A Donation
  • Host an Event
  • Shop Online Store
  • Signature Events
  • L.A. Cancer Challenge
  • Tour De Pier
  • Hirshberg Training Team
  • More
  • News
  • Press
  • Contact

Stay Connected

Join Our E-newsletter

  • Legal and Privacy
  • Financial Information
  • Contact